CD25hi regulatory T cell therapy

N/A

Report date: 2022/11/20 20:50:25

Base Information

Drug NameCD25hi regulatory T cell therapy
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Tregs
Mechanisms of ActionT lymphocyte replacements
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySpain
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesFundacion Publica Andaluza Para La Gestion De La Investigacion En Sevilla
China Registration ClassN/A

Develop Information

Active CompaniesFundacion Publica Andaluza Para La Gestion De La Investigacion En Sevilla
Inactive CompaniesN/A
Active IndicationsGraft vs Host Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A